Stress-Related Chronic Fatigue Syndrome: A Case Report with a Positive Response to Alpha-Methyl-P-Tyrosine (AMPT) Treatment.
Ljungström, Maria, Oltra, Elisa, Pardo, Marta · International journal of molecular sciences · 2024 · DOI
Quick Summary
This case report describes one patient with ME/CFS who had high levels of stress and an overactive stress-response system in his body. He was treated with a medication called alpha-methyl-p-tyrosine (AMPT), which lowers stress chemicals in the body, and his symptoms improved. The report suggests that some people with ME/CFS may have problems with how their body produces and manages stress chemicals, and this medication might help them.
Why It Matters
This case highlights a potentially overlooked biological subtype of ME/CFS characterized by autonomic nervous system dysregulation and catecholamine excess. If AMPT or similar catecholamine-modulating therapies prove effective in future trials, they could offer relief to patients with hyperadrenergic features who do not respond to standard ME/CFS management approaches.
Observed Findings
Patient met CDC/Fukuda ME/CFS diagnostic criteria and had concurrent POTS diagnosis
Patient had genetic polymorphisms associated with altered catecholamine metabolism (COMT variants)
Patient showed symptom improvement during low-to-medium dose AMPT treatment over 12+ months of follow-up
Patient had evidence of hyperadrenergic state (elevated catecholamine-related biochemistry)
Patient did not respond to conventional ME/CFS treatment approaches prior to AMPT
Inferred Conclusions
Some ME/CFS cases may represent a stress-related subtype driven by sympathetic nervous system hyperactivity and monoamine dysregulation
Catecholamine-targeting therapies like AMPT warrant investigation as a potential treatment option for hyperadrenergic ME/CFS phenotypes
Genetic factors affecting catecholamine metabolism may identify patients most likely to benefit from AMPT
Pacing and stress management are relevant adjuncts to pharmacological treatment in stress-related ME/CFS
Remaining Questions
Does AMPT improve symptoms in other ME/CFS patients with hyperadrenergic features, or was this response patient-specific?
What This Study Does Not Prove
This single case report does not establish that AMPT is an effective treatment for ME/CFS broadly, nor does it prove that catecholamine alterations cause ME/CFS in general populations. The improvement could reflect placebo effect, natural disease fluctuation, concurrent lifestyle changes (pacing), or other unmeasured factors. No causal mechanism between AMPT and symptom relief is demonstrated.
Tags
Symptom:Orthostatic IntoleranceFatigue
Biomarker:MetabolomicsGene Expression
Phenotype:Gradual Onset
Method Flag:PEM Not DefinedNo ControlsSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →